BRAIN AG, a Zwingenberg, Germany-based biotechnology company, has raised € 60m in equity funding.
The round was led by existing shareholders MP Beteiligungs-GmbH (Family Office PUTSCH) and MIG Fonds, with participation of several other investors.
The company intends to use the funding for the implementation of its “buy-and-build” industrialization strategy, which focuses on both acquiring suitable target companies and advancing its own value chain (it covers everything from research and product development to B2B and B2C markets) as well as to further advance its technology platforms.
Founded in 1993 and led by Dr Holger Zinke, CEO, BRAIN discovers and develops novel natural BioActive compounds, microbial producer strains, proprietary enzymes and biocatalysts for its customers in the chemical and pharmaceutical as well as in the food and cosmetics industries. The company qualified as a white biotechnology innovation leader in the two innovation alliances funded by the Ministry of Education and Research (BMBF), NatLifE 2020 and ZeroCarb FP.